CMG901
- Generic Name
- CMG901
- Drug Type
- Biotech
- Background
CMG901 is an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payload.
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Phase 3
Recruiting
- Conditions
- Gastric CancerGastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 589
- Registration Number
- NCT06346392
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Phase 2
Recruiting
- Conditions
- Gastric CancerGastroesophageal Junction CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT06219941
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT05702229
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
Phase 1
Completed
- Conditions
- Advanced Solid TumorGastric Cancer(Including Gastroesophageal Junction Adenocarcinoma)Pancreatic Cancer
- Interventions
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Keymed Biosciences Co.Ltd
- Target Recruit Count
- 176
- Registration Number
- NCT04805307
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, China
🇨🇳Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guangdong, China
🇨🇳Affiliated Hospital of Hebei University, Baoding, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath